Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Early Myelofibrosis with High Molecular Risk Mutations
2014-004928-21Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Ruxolitinib with Placebo (2 arms). Primary endpoint: Progression-free survival (PFS-1). Started Dec 2015; status: terminated.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2014-004928-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004928-21.